Audiology Department, Hospital AC Camargo, Aclimação, Sao Paulo, Brazil.
Clin Transl Oncol. 2011 May;13(5):348-52. doi: 10.1007/s12094-011-0665-2.
The objective of this study was to identify the ocurrence of hearing loss in children treated for retinoblastoma using a multidisciplinary approach.
Thirty-two children were evaluated pre- and post-treatment. Eleven children were treated exclusively with enucleation, fifteen with carboplatin and six with cisplatin. Otoacoustic emissions were performed with the ILO 88, before and after the treatment.
In our study we found 5 children (24%) with hearing loss among the 21 evaluated. However in the group of children treated with carboplatin (N=15), 1 case (6.6%) presented hearing loss, while among those treated with cisplatin (N=6) we found 4 cases (66.6%) with hearing loss (p=0.0114).
We concluded that patients who are treated with cisplatin are at risk for developing hearing loss.
本研究的目的是确定采用多学科方法治疗视网膜母细胞瘤的儿童听力损失的发生情况。
对 32 名儿童进行了治疗前和治疗后的评估。11 名儿童仅接受眼球摘除术治疗，15 名儿童接受卡铂治疗，6 名儿童接受顺铂治疗。使用 ILO 88 在治疗前后进行了耳声发射检查。
在我们的研究中，在 21 名接受评估的儿童中发现了 5 名（24%）听力损失儿童。然而，在接受卡铂治疗的儿童组（N=15）中，有 1 例（6.6%）出现听力损失，而在接受顺铂治疗的儿童组（N=6）中，有 4 例（66.6%）出现听力损失（p=0.0114）。
我们得出结论，接受顺铂治疗的患者有发生听力损失的风险。
